UroGen Pharma Ltd. (URGN): Check-out its Performance


UroGen Pharma Ltd. (NASDAQ:URGN) changes shares on Tuesday trading session, with a change of -0.31% or -$0.07 shares. The trading starts at $22.43 and closed at $22.27 throughout the day. The trading session low price was $22.00 and day high was $22.70 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 84767.0 while its average volume is 161.11K. In other hand, the URGN market cap reached to $512.38M.

On May 15, 2020, BRIEF-Urogen Announces Positive Data From Pivotal Olympus Trial Evaluating Jelmyto In Patients With Low-Grade Upper Tract Urothelial Cancer. According to the news reported on Reuters, * UROGEN ANNOUNCES POSITIVE DATA FROM PIVOTAL OLYMPUS TRIAL EVALUATING JELMYTO™ IN PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -4.06% and down -10.77% for month. Its quarterly performance was -5.13% below, while its half year performance is down -25.63%. URGN yearly performance stood at negative -32.11% and fall -33.47% for year-to-date. Current recommendation for UroGen Pharma Ltd. is 1.90.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. URGN EPS (TTM) for 12-month is -5.79. EPS for this year is -6.70%, while for the next year its value is -4.52. Its EPS Q/Q reached -61.10%. It has an EPS of -65.20% down for past five years.

Let’s take a look on the analyst recommendations on URGN for the current month and previous month. For the current month, 6 of 8 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $31.00 – $59.00. Average target price for URGN was reached at $45.57.

The insider ownership moved to 0.90% and institutional holding shifted to 75.50%.

The company posted an EPS (TTM) of -5.79. According to the most recent quarter report on Name, Ur Energy Inc analysts estimated an average EPS of Urban Outfitters, Inc., while ERGO SCIENCE CORPORATION INC EPS posted a year ago period. Analyst Estimated EPS for URGN published in the report was $UroGen Pharma Ltd. – $UTG INC during the same period.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for URGN fall -15.35% for period of 200 days. SMA for 50 days was -12.45% which is showing red signal, while SMA-20 was -6.89%.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in URGN stock. On Jul 27, PFREUNDSCHUH PETER P., Chief Financial Officer, sold 141 trading shares at the cost of $23.51, which valued at 3315.0. On Jul 27, Schoenberg Mark, Chief Medical Officer, sold 70 shares at the cost of $23.51, with total shares of 18,543. On Jun 04, Schoenberg Mark, Chief Medical Officer, sold 349 shares at the cost of 27.51. After this transaction, Schoenberg Mark total shares reached to 18,404 which valued at 9602.0.